Sirius Medical Announces Pintuition Probe Resterilization Clearance

Summation

  • Users now have the flexibility to choose either to only sterilize, sterilize and cover with a sterile sheath or only use a sterile sheath when using the Pintuition Probe, further broadening the acceptability of the technology and lowering access barriers.
  • Sirius Medical, a leader in value-based healthcare and surgical marker navigation received 510(k) clearance early in 2023 for their Sirius Pintuition® Probe, used during surgery, to be resterilized by users in STERRAD NX and NX100 systems.
  • The company also recently announced their partnership with Surgeons Choice and Surgical Supplies to provide the Australian and New Zealand surgical communities with surgical marker navigation.

Sirius Medical, a leader in value-based healthcare and surgical marker navigation received 510(k) clearance early in 2023 for their Sirius Pintuition® Probe, used during surgery, to be resterilized by users in STERRAD NX and NX100 systems.

Pintuition is a surgical marker navigation system that provides surgeons with both distance and direction to non-palpable tumors with exceptional accuracy. Patients benefit from enhanced diagnostic accuracy, reduced procedure times, and improved treatment planning.

Users now have the flexibility to choose either to only sterilize, sterilize and cover with a sterile sheath or only use a sterile sheath when using the Pintuition Probe, further broadening the acceptability of the technology and lowering access barriers.

“This FDA clearance is in line with the values we are bringing to our customers worldwide, simplicity, flexibility and accessibility, and affordability,” says Bram Schermers, CEO Sirius Medical. “At Sirius Medical we take pride in listening to our customers bringing continuous product enhancement to help deliver cost-efficient and better patient care with ease of use.”

The company also recently announced their partnership with Surgeons Choice and Surgical Supplies to provide the Australian and New Zealand surgical communities with surgical marker navigation.

Other FDA News of Interest

Tris Pharma Receives U.S. FDA Approval for Once-Daily ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, the First-and-Only Liquid Non-Stimulant ADHD Medication

ONYDA XR is indicated for the treatment of ADHD as monotherapy or as adjunctive therapy to approved CNS stimulant medications in pediatric patients six years and older. The first non-stimulant ADHD medication, with nighttime dosing, adds to Tris Pharma’s established portfolio of leading ADHD therapies and reinforces company's commitment to individuals with ADHD.

Indica Labs Receives FDA Clearance for HALO AP Dx Digital Pathology Platform for Use with Hamamatsu Images Acquired with the NanoZoomer® S360MD Slide Scanner

Indica Labs, an industry leader in AI-powered digital pathology solutions, and Hamamatsu Photonics K.K., a pioneer in whole slide imaging systems, announce that the...

FDA Grants AI-Powered Notal Vision Home OCT “SCANLY” De Novo Marketing Authorization

“We are very excited to receive FDA authorization to market SCANLY Home OCT as the first-ever patient self-operated, home-use device that gives physicians remote access to high-resolution, cross-sectional retinal images and AI-based analytical biomarkers of their patients eyes between office visits,” said Kester Nahen, PhD, CEO of Notal Vision. “We look forward to supporting our referring physicians in navigating their wet AMD patients’ care.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy